Table 3 Predicted costs and QALYs by treatment strategy and population, per patient over 15 years
Pseudophakic population | Phakic population | ||||
|---|---|---|---|---|---|
FAc 0.2 μg/day implant | Usual Care | Dexamethasone | FAc 0.2 μg/day implant | Usual care | |
Costs | |||||
Drug – SE, of which: | £7982 | £3237 | £4841 | £8078 | £3330 |
Corticosteroidsa | £7092 | £0 | £2478 | £7140 | £0 |
Other treatments | £890 | £3237 | £2363 | £938 | £3330 |
Drug – FE | £5580 | £5193 | £5319 | £5822 | £5348 |
Corticosteroidsa | £986 | £0 | £364 | £1235 | £0 |
Other treatments | £4594 | £5193 | £4955 | £4587 | £5348 |
Monitoring – SE | £4538 | £6366 | £5944 | £4676 | £6550 |
Monitoring – FE | £525 | £551 | £544 | £535 | £567 |
Adverse event | £1935 | £1432 | £1415 | £3666 | £3095 |
Blindness | £114 | £194 | £163 | £188 | £227 |
Administration | £1442 | £2078 | £2114 | £1460 | £2139 |
Total costs | £22,117 | £19,051 | £20,340 | £24,425 | £21,255 |
QALYs | 5.78 | 5.59 | 5.65 | 6.36 | 6.25 |